BioInsights - Sharing best practices in AAV vector scale-up

Sharing best practices in AAV vector scale-up

Cell & Gene Therapy Insights 2023; 9(1), 19–23

DOI: 10.18609/cgti.2023.003

Published: 16 January 2023
Interview
Seth Levy

David McCall, Commissioning Editor, BioInsights, talks to Seth Levy, Director of Bioprocess Development, Modalis Therapeutics


Seth Levy, joined Modalis Therapeutics in 2021 as Director of Bioprocess Development to build and oversee internal process development and analytics efforts, as well as manage external manufacturing. Prior to Modalis, Seth lead teams in Manufacturing Science and Technology and Small-Scale Development for AAV and LV manufacturing at Viral Vectors Services. Seth worked in gene therapy R&D before his time at a CDMO and drove numerous AAV projects including basic biology research, capsid engineering, and translational gene therapy approaches at Sanofi Genzyme and academia.